Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
e-Letters: Comments and Responses

Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858–1867

  1. David P. Sonne1⇑ and
  2. Filip K. Knop1,2
  1. 1Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
  2. 2The Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  1. Corresponding author: David P. Sonne, dpsonne{at}gmail.com.
Diabetes Care 2015 Dec; 38(12): e215-e215. https://doi.org/10.2337/dc15-1794
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

In the task of alluding to the mode of action of metformin, Xu et al. (1) examined 131 fasting serum metabolites in three independent cross-sectional cohort studies. The authors found decreased concentrations of three metabolites (acyl-alkyl phosphatidylcholines [PCs]) in patients with type 2 diabetes treated with metformin compared with control groups not using glucose-lowering oral medication. The reduction of these metabolites was associated with lower plasma concentrations of LDL cholesterol, which was partially mediated by the three PCs. Statistical analyses suggested that the reduced PC concentrations were explained by metformin’s effect on AMPK in the liver. Moreover, the metabolite variations were associated with 17 genes (including FADS genes, which function in fatty acid metabolism).

Xu et al. (1) are to be congratulated for their comprehensive study that brings substantial new knowledge to the enigmatic topic of metformin and its pleiotropic mode of action. However, in terms of LDL cholesterol reduction, we wish to draw attention to one mode of action that was not addressed in the study. The cholesterol-lowering effects of metformin have long been recognized (2). For some years now, we have also known that metformin represses intestinal bile acid absorption—an effect that likely arises from interaction with the bile acid transport system in the distal ileum (3). Reduced bile acid absorption leads to increased bile acid synthesis from cholesterol (4). This is largely exerted at the level of the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1) by feedback inhibition, which is partly mediated by the farnesoid X receptor (FXR) regulation of CYP7A1 gene expression (4). Bile acid synthesis is also repressed by the gut hormone fibroblast growth factor 19, which is synthesized in ileal enterocytes in response to bile acid–induced FXR activation and released into the portal circulation (4). Naturally, interruption of the enterohepatic circulation by the removal of the distal ileum or by the administration of bile acid sequestrants enhances fecal bile acid excretion. Consequently, bile acid synthesis from cholesterol is increased, leading to an enhanced demand for cholesterol in the hepatocytes, which is achieved by LDL receptor upregulation. This increases uptake of cholesterol-rich lipoproteins, leading to a decrease in total cholesterol and LDL cholesterol. Bile acid sequestrants were the first lipid-altering drugs to show an ability to reduce the risk of coronary heart disease (5). Administration of the bile acid sequestrant cholestyramine demonstrated a 19% risk reduction of coronary heart disease death and/or nonfatal myocardial infarction compared with placebo (5). LDL cholesterol concentrations were reduced by 13% and total mortality was reduced by 7%. Considering these data, we find it is plausible that part of metformin’s pleiotropic effects on lipids involves interruption of the enterohepatic circulation of bile acids, leading to increased bile acid synthesis, which eventually reduces circulating LDL cholesterol concentrations.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

  • © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Xu T,
    2. Brandmaier S,
    3. Messias AC, et al
    . Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care 2015;38:1858–1867
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Giugliano D,
    2. De Rosa N,
    3. Di Maro G, et al
    . Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993;16:1387–1390
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Scarpello JH,
    2. Hodgson E,
    3. Howlett HC
    . Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15:651–656
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Hofmann AF,
    2. Hagey LR
    . Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 2014;55:1553–1595
    OpenUrlAbstract/FREE Full Text
  5. ↵
    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–364
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 38 (12)

In this Issue

December 2015, 38(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858–1867
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858–1867
David P. Sonne, Filip K. Knop
Diabetes Care Dec 2015, 38 (12) e215; DOI: 10.2337/dc15-1794

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858–1867
David P. Sonne, Filip K. Knop
Diabetes Care Dec 2015, 38 (12) e215; DOI: 10.2337/dc15-1794
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
  • Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
  • Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957
Show more e-Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.